17 August 2022
Disruptive technologies such as CRISPR and next generation sequencing (NGS) have the potential to change in vitro diagnostics. In this video, we hear from Dr. Chris Kavanagh and Kerry Trice about the challenges with these technologies and how Merck can be a supportive partner to help companies to bring assays utilizing them to market.